Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Stayhealthy and OncoGambit Release Mobile Coaching Platform to Support Breast Cancer Survivors and Promote Healthy Behaviors for Cancer Prevention


MONROVIA, Calif., Dec. 10, 2019 /PRNewswire-PRWeb/ -- Stayhealthy, the first company to combine patented healthcare solutions with augmented reality technology, and OncoGambit, the first computer-aided individualized cancer treatment confirmation resource, announced today the launch of a new mobile platform dedicated to assisting cancer survivors to adopt healthy lifestyle changes. The platform will be introduced at the San Antonio Breast Cancer Symposium on December 11.

"With over 3.8 million breast cancer survivors in the U.S., the need addressed by the OWL platform could not be timelier," said Dr. Colin Hill, Stayhealthy's COO and Chief Science Officer. "Current available support services are often insufficient to meet this growing need."

"Cancer survivors need ongoing guidance and support after cancer diagnosis to achieve their best outcome," stated Dr. Hannah Luu, CEO and founder of OncoGambit. "With the most advanced resources and tools, OWL provides a unique after-care support plan for ongoing support in addition to recurrence prevention."

"Almost 60% of all cancer survivors suffer from excess body fat," added John Collins, CEO of Stayhealthy. "We know from research that there is a 30% increased risk of disease recurrence and death from breast cancer related to excess body fat. OWL was also developed specifically to help survivors deal with this growing problem."

The OWL app is a game changer that is positioned as an easily accessible, comprehensive survival care guide for cancer survivors. The app uses a chatbot navigation tool to guide users through a series questions and answers spreading over four modules including education (with an emphasis on breast cancer education in treatment and cancer recurrence prevention), daily activity and movement plan, conscious eating coach, and mindfulness practice?all allowing for real time interaction with the user.

The addition of augmented reality experiences adds a powerful dimension to amplifying the platform's rich content. Approximately 23,000 oncologists are currently responsible for nearly 17 million cancer survivors in the U.S. and studies show that 80% of these survivors rely on their oncologist for nutrition, exercise, and psycho-social guidance. While initially focused on breast cancer survivors, OWL will eventually address and promote healthy behaviors for the prevention of all cancers in future versions.

 

SOURCE Stayhealthy INC


These press releases may also interest you

at 15:01
The Center for Youth Wellness announces the release of an in-depth study on the health-related cost of adverse childhood experiences (ACEs) in the state of California. A number of studies have investigated the cost of...

at 14:56
Aridis Pharmaceuticals, Inc. (the "Company") presented a comprehensive profile of its APEXtm platform technology at the antibody and cell engineering conference 19th Annual PepTalk: The Protein Science Week on Friday, January 24, 2020 in San Diego,...

at 14:30
The "Global Non-Injectable Insulin Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive summary of the non-injectable insulin market, along with detailed profiles of key market players...

at 14:20
Global Bilirubin Blood Test Market 2020-2024 The analyst has been monitoring the global bilirubin blood test market and it is poised to grow by USD 562.5 mn during 2020-2024, progressing at a CAGR of 8% during the forecast period. Our reports on...

at 14:10
The report on the global gastrointestinal drugs market provides qualitative and quantitative analysis for the period from 2017 to 2025. Read the full report: https://www.reportlinker.com/p05112184/?utm_source=PRN The report predicts the global...

at 14:05
Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced the closing of an upsized $17.3 million private financing. The financing comprised existing and new...



News published on 10 december 2019 at 11:00 and distributed by: